Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
